Clinical Study of Butylphthalide and Sodium Chloride Injection Combined with Sodium Ozagrel Injection in the Treatment of Acute Progressive Cerebral Infarction

WANG Yulin; ZHONG Chunzheng; GUO Chunxuan; GAO Yuanjie

doi:10.14009/j.issn.1672-2124.2020.04.012

您当前的位置：

首页 >

文章列表页 >

Clinical Study of Butylphthalide and Sodium Chloride Injection Combined with Sodium Ozagrel Injection in the Treatment of Acute Progressive Cerebral Infarction

更新时间：2022-10-08

- Clinical Study of Butylphthalide and Sodium Chloride Injection Combined with Sodium Ozagrel Injection in the Treatment of Acute Progressive Cerebral Infarction
- Vol. 20, Issue 4, Pages: 428-431(2020)
- 作者机构：
  
  儋州市人民医院神经内科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.04.012
  CLC： R743.3
- Published：2020，
扫描看全文
[1]王御林,钟纯正,郭春宣,高元杰.丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗急性进展性脑梗死的临床研究[J].中国医院用药评价与分析,2020,20(04):428-431.

WANG Yulin, ZHONG Chunzheng, GUO Chunxuan, et al. Clinical Study of Butylphthalide and Sodium Chloride Injection Combined with Sodium Ozagrel Injection in the Treatment of Acute Progressive Cerebral Infarction. [J]. 20(4):428-431(2020)
[1]王御林,钟纯正,郭春宣,高元杰.丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗急性进展性脑梗死的临床研究[J].中国医院用药评价与分析,2020,20(04):428-431. DOI： 10.14009/j.issn.1672-2124.2020.04.012.

WANG Yulin, ZHONG Chunzheng, GUO Chunxuan, et al. Clinical Study of Butylphthalide and Sodium Chloride Injection Combined with Sodium Ozagrel Injection in the Treatment of Acute Progressive Cerebral Infarction. [J]. 20(4):428-431(2020) DOI： 10.14009/j.issn.1672-2124.2020.04.012.

摘要

目的:探讨丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗急性进展性脑梗死的临床疗效。方法:对儋州市人民医院2017年6月至2019年5月收治的116例急性进展性脑梗死患者进行回顾性研究

根据治疗方式的不同分为观察组、对照组

每组58例。对照组患者采用奥扎格雷钠注射液治疗

观察组患者采用丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗。比较两组患者临床疗效

治疗前后美国国立卫生院卒中神经功能缺损评分量表（national institutes of health stroke scale

NIHSS）评分、Barthel指数及凝血因子水平变化和不良反应发生情况的差异。结果:观察组患者的总有效率为89. 66%（52/58）

明显高于对照组的74. 14%（43/58）

差异有统计学意义（P <0. 05）。治疗后

两组患者NIHSS评分明显低于治疗前

Barthel指数明显高于治疗前;且观察组患者NIHSS评分明显低于对照组

Barthel指数明显高于对照组

上述差异均有统计学意义（P <0. 05）。治疗后

两组患者活化部分凝血活酶时间（APTT）、凝血酶原时间（PT）及国际标准化比值（INR）水平均明显高于治疗前

纤维蛋白原（FIB）水平明显低于治疗前;且观察组患者APTT、PT及INR水平明显高于对照组

FIB水平明显低于对照组

上述差异均有统计学意义（P <0. 05）。观察组、对照组患者不良反应发生率[13. 79%（8/58） vs. 10. 34%（6/58）]的差异无统计学意义（P> 0. 05）。结论:丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗急性进展性脑梗死的临床疗效显著

可有效减轻患者神经功能受损现象

改善凝血功能。

Abstract

OBJECTIVE: To probe into the clinical efficacy of butylphthalide and sodium chloride injection combined with sodium ozagrel injection in the treatment of acute progressive cerebral infarction. METHODS: 116 patients with acute progressive cerebral infarction admitted into Danzhou People’s Hospital from Jun. 2017 to May2019 were retrospectively analyzed and divided into observation group and control group according to different therapeutic regimens

with 58 cases in each group. The control group was treated with sodium ozagrel injection

while the observation group was given butylphthalide and sodium chloride injection combined with sodium ozagrel injection.The clinical efficacy

differences in National Institutes of Health Stroke Scale（ NIHSS） scores

Barthel indices

changes of blood coagulation factor and incidences of adverse drug reactions of the two groups were compared.RESULTS: The total effective rate of observation group was 89. 66%（ 52/58）

which was significantly higher than that of the control group（ 74. 14%

43/58）

with statistically significant difference（ P < 0. 05）. After treatment

the NIHSS scores of both groups were significantly decreased

while the Barthel indices of both groups were significantly increased; the NIHSS score of observation group was significantly lower than that of the control group

while the Barthel index of observation group was significantly higher than that of the control group

with statistically significant differences（ P < 0. 05）. After treatment

the activated partial thromboplastin time（ APTT）

prothrombin time（ PT）and international normalized ratio（ INR） levels of both groups were significantly increased

while the fibrinogen（ FIB）level was significantly decreased; the APTT

PT and INR levels of observation group were significantly higher than those of the control group

while the FIB level of observation group was significantly lower than that of the control group

with statistically significant differences（ P < 0. 05）. The incidences of adverse drug reactions of observation group and control group were respectively 13. 79%（ 8/58） and 10. 34%（ 6/58）

the difference had no statistical significance（ P > 0. 05）. CONCLUSIONS: The clinical efficacy of butylphthalide and sodium chloride injection combined with sodium ozagrel injection in the treatment of acute progressive cerebral infarction is remarkable

which can effectively relieve the damage of neurological function and improve coagulation function.

关键词

丁苯酞氯化钠注射液奥扎格雷钠注射液急性进展性脑梗死临床疗效神经功能凝血因子

Keywords

Butylphthalide and sodium chloride injectionSodium ozagrel injectionAcute progressive cerebral infarctionClinical efficacyNeurological functionCoagulation factors

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on Pleiotropy and Safety of Pitavastatin in Patients with Cerebral Infarction

Huanshao Capsules Combined with Tamsulosin Hydrochloride in the Treatment of Premature Ejaculation of Spleen and Kidney Yang Deficiency Type

Effects of Fiberoptic Bronchoalveolar Lavage Combined with Azithromycin on Immune Function, Serum MCP-4, MAPK and CysLTR1 in Children with Mycoplasma Pneumoniae Pneumonia

Clinical Efficacy and Safety of Osimertinib in the Treatment of EGFR Gene Mutation-Positive NSCLC Patients in the Real World

Effects of Gastrodin Combined with Anisomine Hydrobromate on Neurological Function in the Elderly with Cerebral Small Vessel Disease and Cognitive Dysfunction

Related Author

PAN Dan

SU Weiwei

LI Li

CHEN Kuixia

YUAN Ying

ZHAO Kexin

DOU Jianguo

JIANG Daobin

Related Institution

Dept. of Respiratory Medicine,the Third People’s Hospital of Langfang

Dept. of Neurology, Hebei Petrochina Central Hospital

Dept. of Urology, Dazu District People’s Hospital

Pediatric Intensive Care Unit, Chengdu Women’s and Children’s Central Hospital

Dept. of Pediatrics, Nanchong Central Hospital

⁰